Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H1 2018
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H1 2018
SUMMARY
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Parkinson's Disease, Anxiety Disorders, Autism, Depression, Drug Addiction, Infantile Spasm (West Syndrome), Multiple Sclerosis, Obsessive-Compulsive Disorder, Psychosis, Status Epilepticus and Substance (Drug) Abuse.
The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Parkinson's Disease, Anxiety Disorders, Autism, Depression, Drug Addiction, Infantile Spasm (West Syndrome), Multiple Sclerosis, Obsessive-Compulsive Disorder, Psychosis, Status Epilepticus and Substance (Drug) Abuse.
The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
- The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Domain Therapeutics SA
Prexton Therapeutics SA
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXT-2331 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GLUR4 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0418506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing
Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction
Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial
Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Mar 07, 2016: Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model
Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson’s Disease In Journal Of Pharmacology And Experimental Therapeutics
Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinson?s Disease
Feb 25, 2008: Addex In Collaboration With Merck & Co., Inc. Achieves First Milestone In Parkinson’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Domain Therapeutics SA
Prexton Therapeutics SA
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXT-2331 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GLUR4 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0418506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing
Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction
Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial
Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Mar 07, 2016: Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model
Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson’s Disease In Journal Of Pharmacology And Experimental Therapeutics
Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinson?s Disease
Feb 25, 2008: Addex In Collaboration With Merck & Co., Inc. Achieves First Milestone In Parkinson’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Addex Therapeutics Ltd, H1 2018
Pipeline by Domain Therapeutics SA, H1 2018
Pipeline by Prexton Therapeutics SA, H1 2018
Dormant Projects, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Addex Therapeutics Ltd, H1 2018
Pipeline by Domain Therapeutics SA, H1 2018
Pipeline by Prexton Therapeutics SA, H1 2018
Dormant Projects, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Addex Therapeutics Ltd
Domain Therapeutics SA
Prexton Therapeutics SA
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Addex Therapeutics Ltd
Domain Therapeutics SA
Prexton Therapeutics SA
